Dr Katims on the Feasibility of scRNA-seq in FGFR3+ Upper Tract Urothelial Carcinoma

Video

In Partnership With:

Andrew Katims, MD, MPH, discusses the feasibility of using single-cell RNA-sequencing in FGFR3-mutated upper tract urothelial carcinoma

Andrew Katims, MD, MPH, urologic oncology fellow, Memorial Sloan Kettering Cancer Center, discusses the feasibility of using single-cell RNA-sequencing (scRNA-seq) in FGFR3-mutated upper tract urothelial carcinoma.

At the 2023 American Urological Association Annual Meeting, Katims and colleagues presented findings from an investigation on the use of scRNA-seq to characterize the immune phenotype of FGFR3-mutated upper tract urothelial carcinoma. Using 7 individual tissue samples obtained from patients who were treatment naïve, researchers identified 19 immune cell clusters with unique biologic functions, including 8 T-cell clusters, which were categorized into FGFR3-mutated vs FGFR3 wild-type samples. FGFR-mutated disease had a T-cell phenotype characterized by a high frequency of active/exhausted Th17-like CD4 cells, lower levels of regulatory T cells, and increased amounts of CD8/cytotoxic cells in naïve state.

Although single-cell sequencing currently has a role in a research setting, it is not practical to use in a clinical setting at this point, Katims explains. He notes that several factors currently limit the practicality of scRNA-seq in a clinical setting, including its high cost.

However, the costs of bulk RNA sequencing are steadily falling, and results from bulk testing have been similar to those seen with scRNA-seq, Katims continues. Although scRNA-seq can provide a more granular picture, the targeted gene sequencing, followed by RNA sequencing, appear to be the current trajectory for testing patients with upper urothelial tract carcinoma, Katims notes. scRNA-seq could have a role; however, it will be important to validate these results in bulk RNA sequencing, which can be more affordable and have a more practical clinical application, Katims concludes.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD